Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0C0KP
|
|||
Former ID |
DIB008734
|
|||
Drug Name |
AllerB
|
|||
Indication | Allergy [ICD-11: 4A80-4A85; ICD-10: T78.4; ICD-9: 995.3] | Phase 2b | [1] | |
Company |
Anergis SA
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Phospholipase A2 (PLA2G1B) | Target Info | Inhibitor | [2] |
BioCyc | Phospholipases | |||
KEGG Pathway | Glycerophospholipid metabolism | |||
Ether lipid metabolism | ||||
Arachidonic acid metabolism | ||||
Linoleic acid metabolism | ||||
alpha-Linolenic acid metabolism | ||||
Metabolic pathways | ||||
Ras signaling pathway | ||||
Vascular smooth muscle contraction | ||||
Pancreatic secretion | ||||
Fat digestion and absorption | ||||
Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | |||
Reactome | Acyl chain remodelling of PC | |||
Acyl chain remodelling of PE | ||||
Acyl chain remodelling of PI | ||||
WikiPathways | Glycerophospholipid biosynthesis |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of Anergis SA. | |||
REF 2 | Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):747-54. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.